Hadassah

Hadassah Clinical Trial Reveals Safety and Efficacy of Stem Cell Technology in Treating ALS

Wednesday, Feb 15 2012

"This may represent the biggest hope in the field of degenerative diseases like ALS," Prof. Dimitrios Karussis, head of the Hadassah University Medical Center's Multiple Sclerosis Center, said about the clinical trial just completed at Hadassah where stem cells were used to treat Amyotrophic Lateral Sclerosis (ALS).

Even though this was a trial to determine the safety of the technology, early clinical follow up of the patients demonstrated an improvement in breathing and swallowing ability as well as in muscular power. "I am very excited about the safety results, as well as the indications of efficacy," Prof. Karussis said. The initial patients who were treated with BrainStorm Cell Therapeutics' NurOwn™ stem cell technology experienced no significant side effects in this Phase I/II clinical trial. As a result, Hadassah's ethics and safety committee has now granted BrainStorm approval to proceed with treating additional patients.

NurOwn™ technology processes adult human stem cells that are present in bone marrow and are capable of self-renewal and differentiation into many other cell types. A progressive neurodegenerative disease, ALS, often referred to as Lou Gehrig's disease, affects nerve cells in the brain and the spinal cord. With this technology, the bone marrow cells are induced to differentiate into cells capable of releasing neurotrophic factors which can help ALS patients. According to the ALS Association, approximately 5,600 people in the United States are diagnosed with ALS each year and it is estimated that as many as 30,000 Americans may have the disease at any given time.

The study, led by Prof. Karussis, is being conducted in conjunction with a scientific team from BrainStorm.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Tuesday, Jan 10 2017

From Locked Jaw to Osteoarthritis: Hadassah Discovery Leads to New Treatment

What began as a solution to locked jaw--temporomandibular joint (TMJ) disorder--has led to the creation of a novel non-opioid pharmaceutical candidate for the treatment of osteoarthritis pain, thanks to a Hadassah Medical Organization discovery and collaboration with colleagues at the Hebrew University and the Technion.

READ MORE ›
alt_text

Monday, Jan 9 2017

Soldiers Rushed to Hadassah After Sunday's Terrorist Attack

On Sunday January 8, four soldiers were killed and 17 wounded, when a terrorist rammed his vehicle into them.

READ MORE ›
alt_text

Monday, Jan 9 2017

Prime Minister Netanyahu visits terror survivors at Hadassah Hospital

Prime Minister Benjamin Netanyahu and Health Minister Yaakov Litzman visited terror victims hospitalized at Hadassah Hospital Ein Kerem after a terrorist rammed his flatbed truck into a group of soldiers on an IDF cultural field trip in Jerusalem. Four were killed, and 11 patients underwent treatment at Hadassah hospitals: 9 at Ein Kerem and 2 at Mount Scopus.

READ MORE ›
alt_text

Friday, Jan 6 2017

World-First Newborn Intestinal Surgery Saves Baby Girl at Hadassah

A baby girl whose intestines formed outside of her abdomen was saved by a world-first surgical procedure following her birth at Hadassah Hospital Ein Kerem.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More